Fintel reports that on February 11, 2025, Raymond James downgraded their outlook for Third Harmonic Bio (NasdaqGM:THRD) from ...

American biotech Third Harmonic Bio and Inventiva have announced plans to reduce their respective workforces by 50% as part of cost-cutting measures. Both companies are shifting their focus to a ...

Raymond James downgraded Third Harmonic Bio (THRD) to Market Perform from Outperform.Maximize Your Portfolio with Data Driven Insights:Leverage ...

As previously reported, Raymond James downgraded Third Harmonic Bio (THRD) to Market Perform from Outperform and removed the firm’s prior $18 ...

THB335 Phase 1 data support advancement into Phase 2 clinical trial in chronic spontaneous urticaria (CSU) Company initiating process to leverage balance sheet strength to maximize shareholder value ...

The full results of the Phase 1 trial will be presented at the AAAAI/WAO Joint Congress on Sunday, March 2, 2025. Meanwhile, Third Harmonic Bio plans to proceed with THB335 development activities ...

James made a notable change in their assessment of Third Harmonic (NASDAQ:HLIT) Bio (NASDAQ:THRD), downgrading the biotechnology company's stock rating from Outperform to Market Perform. According to ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

Republican lawmakers in several states have Medicaid expansion in their crosshairs, energized by President Donald Trump’s return to the White House and a GOP-controlled Congress set on reducing spendi ...

Lipella Pharmaceuticals LIPO stock moved upwards by 49.5% to $4.56 during Tuesday's pre-market session. The market value of their outstanding shares is at $5.5 million. IN8bio INAB shares increased by ...